Literature DB >> 7822145

A quantitative system to evaluate diabetic retinopathy from fundus photographs.

S S Feman1, T C Leonard-Martin, J S Andrews, C C Armbruster, T L Burdge, J D Debelak, A Lanier, A G Fischer.   

Abstract

PURPOSE: To evaluate a quantitative system to measure the early lesions of diabetic retinopathy seen in stereoscopic fundus photographs.
METHODS: Using a quantitative classification system, photographs of 4657 eyes (7 stereo pairs of 35-mm slides per eye) were scored for 16 diabetic lesions. A single severity level (identical to the ETDRS Interim Scale) was calculated for each eye. The reliability of this technique, and its reproducibility by independent examiners, was evaluated for individual lesions and severity levels using percent agreement, kappa, and weighted kappa statistics.
RESULTS: This quantitative technique demonstrated an "almost perfect" agreement (weighted kappa > or = 0.810) on all but one lesion by independent observers. For the severity levels, there was a 95.7% perfect agreement (kappa = 0.9428). The reproducibility of agreement over time was "almost perfect" on all but four lesions; with 88% perfect agreement (kappa = 0.8394) for severity levels.
CONCLUSIONS: When used to evaluate the early lesions of diabetic retinopathy, the Vanderbilt Classification System is highly reliable between graders and over time. This system can gather quantitative data and evaluate incremental changes in an accurate, reproducible manner.

Entities:  

Mesh:

Year:  1995        PMID: 7822145

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study.

Authors:  Maria L Ribeiro; Andras I Seres; Angela M Carneiro; Michael Stur; Alain Zourdani; Patricia Caillon; José G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

2.  The Vanderbilt Classification System in the evaluation of diabetic retinopathy patients treated with Alredase.

Authors:  S S Feman; T C Leonard-Martin; J R Redman
Journal:  Trans Am Ophthalmol Soc       Date:  1996

3.  Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial.

Authors:  Marina Trento; Olga Durando; Sonia Lavecchia; Lorena Charrier; Franco Cavallo; Miguel Angelo Costa; Cristina Hernández; Rafael Simó; Massimo Porta
Journal:  Endocrine       Date:  2016-09-14       Impact factor: 3.633

4.  Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity.

Authors:  Graham E Quinn; Gui-shuang Ying; Ebenezer Daniel; P Lloyd Hildebrand; Anna Ells; Agnieshka Baumritter; Alex R Kemper; Eleanor B Schron; Kelly Wade
Journal:  JAMA Ophthalmol       Date:  2014-10       Impact factor: 7.389

5.  The Global Education Network for Retinopathy of Prematurity (Gen-Rop): Development, Implementation, and Evaluation of A Novel Tele-Education System (An American Ophthalmological Society Thesis).

Authors:  R V Paul Chan; Samir N Patel; Michael C Ryan; Karyn E Jonas; Susan Ostmo; Alexander D Port; Grace I Sun; Andreas K Lauer; Michael F Chiang
Journal:  Trans Am Ophthalmol Soc       Date:  2015

6.  Utilisation of optical coherence tomography and optical coherence tomography angiography to assess retinal neovascularisation in diabetic retinopathy.

Authors:  Joanna DaCosta; Devangna Bhatia; Oonagh Crothers; James Talks
Journal:  Eye (Lond)       Date:  2021-04-28       Impact factor: 3.775

7.  Elevated RBP4 plasma levels were associated with diabetic retinopathy in type 2 diabetes.

Authors:  Jia-Ying Li; Xian-Xian Chen; Xiao-Hua Lu; Chuang-Biao Zhang; Qi-Ping Shi; Lie Feng
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

8.  Automatic Exudate Detection from Non-dilated Diabetic Retinopathy Retinal Images Using Fuzzy C-means Clustering.

Authors:  Akara Sopharak; Bunyarit Uyyanonvara; Sarah Barman
Journal:  Sensors (Basel)       Date:  2009-03-24       Impact factor: 3.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.